Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000947871-25-000927
Filing Date
2025-10-27
Accepted
2025-10-27 17:19:23
Documents
1
Period of Report
2025-10-23

Document Format Files

Seq Description Document Type Size
1 ownership.html 4  
1 ownership.xml 4 5828
  Complete submission text file 0000947871-25-000927.txt   8064
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Reporting) CIK: 0001055951 (see all company filings)

State of Incorp.: DE
Type: 4 | Act: 34 | File No.: 001-39539 | Film No.: 251420656

Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 212-739-6400
OrbiMed Capital GP V LLC (Reporting) CIK: 0001615374 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39539 | Film No.: 251420655

Mailing Address 400 ALEXANDER PARK DRIVE SUITE 301 PRINCETON NJ 08540
Business Address 400 ALEXANDER PARK DRIVE SUITE 301 PRINCETON NJ 08540 (609) 642-6670
PMV Pharmaceuticals, Inc. (Issuer) CIK: 0001699382 (see all company filings)

EIN.: 463218129 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)